Patient demographics and clinical characteristics
| Total cohort | Female | Male | P value | |
| No of patients, n (%) | 9306 | 3680 (39.54) | 5626 (60.46) | <0.001 |
| Age, continuous, mean±SD | 49.21±14.56 | 50.02±14.51 | 48.67±14.61 | <0.001 |
| Geographic region,5 n (%) | 0.001 | |||
| Northeast | 2349 (25.24) | 882 (23.97) | 1467 (26.08) | – |
| North central | 1891 (20.32) | 738 (20.05) | 1153 (20.49) | – |
| South | 3826 (41.11) | 1593 (43.29) | 2233 (39.69) | – |
| West | 1224 (13.15) | 456 (12.39) | 768 (13.65) | – |
| Unknown | 16 (0.17) | 11 (0.3) | 5 (0.09) | – |
| Health plan type, n (%) | <0.001 | |||
| Comprehensive | 292 (3.21) | 136 (3.7) | 156 (2.77) | – |
| Exclusive provider organisation | 48 (0.53) | 13 (0.35) | 35 (0.62) | – |
| Health maintenance organisation | 1003 (11.04) | 396 (10.76) | 607 (10.79) | – |
| Point of service plan | 817 (8.99) | 317 (8.61) | 500 (8.89) | – |
| Preferred provider organisation | 5184 (57.04) | 2106 (57.23) | 3078 (54.71) | – |
| Point of service plan with capitation | 93 (1.02) | 37 (1.01) | 56 (1.00) | – |
| Consumer driven health plan | 878 (9.66) | 317 (8.61) | 561 (9.97) | – |
| High deductible health plan | 774 (8.52) | 255 (6.93) | 519 (9.23) | – |
| Missing | 217 (2.39) | – | – | – |
| Diagnostic tests, n (%) | ||||
| 12-lead ECG | 2817 (30.27) | 1132 (30.76) | 1685 (29.95) | 0.405 |
| Holter | 597 (6.42) | 237 (6.44) | 360 (6.40) | 0.937 |
| Cardiac stress test | 727 (7.81) | 251 (6.82) | 476 (8.46) | 0.004 |
| Coronary angiography | 84 (0.90) | 34 (0.92) | 50 (0.89) | 0.861 |
| Any myocardial imaging | ||||
| Echocardiogram | 1938 (20.83) | 806 (21.9) | 1132 (20.12) | 0.039 |
| CT | 48 (0.52) | 17 (0.46) | 31 (0.55) | 0.558 |
| MRI | 334 (3.59) | 125 (3.40) | 209 (3.71) | 0.420 |
| Nuclear or positron emission tomography | 214 (2.30) | 83 (2.26) | 131 (2.33) | 0.818 |
| Any HCM genetic test | 158 (1.70) | 65 (1.77) | 93 (1.65) | 0.679 |
| Comorbidities of Interest, n (%) | ||||
| Ventricular tachycardia/ventricular fibrillation | 680 (7.31) | 223 (6.06) | 457 (8.12) | 0.001 |
| Coronary artery disease | 968 (10.40) | 337 (9.16) | 631 (11.22) | 0.002 |
| Diabetes | 1337 (14.37) | 575 (15.63) | 762 (13.54) | 0.005 |
| Dyslipidaemia | 1943 (20.88) | 687 (18.67) | 1256 (22.32) | <0.001 |
| Hypertension | 3979 (42.76) | 1632 (44.35) | 2347 (41.72) | 0.012 |
| Stroke | 144 (1.55) | 69 (1.88) | 75 (1.33) | 0.038 |
| Concomitant medication, n (%) | ||||
| ACEi | 1057 (11.36) | 364 (9.89) | 693 (12.32) | 0.001 |
| ARB | 806 (8.66) | 331 (9.00) | 475 (8.44) | 0.355 |
| Antiarrhythmics | 668 (7.18) | 241 (6.55) | 427 (7.59) | 0.058 |
| Anticoagulants | 756 (8.12) | 254 (6.9) | 502 (8.92) | 0.001 |
| Beta blockers | 4114 (44.21) | 1571 (42.69) | 2543 (45.20) | 0.017 |
| Calcium channel blockers | 1736 (18.65) | 699 (18.99) | 1037 (18.43) | 0.496 |
| Surgical procedures, n (%) | ||||
| Coronary revascularisation | ||||
| Coronary artery bypass graft | 3 (0.03) | 1 (0.03) | 2 (0.04) | 0.826 |
| Percutaneous coronary intervention | 6 (0.06) | 2 (0.05) | 4 (0.07) | 0.756 |
| Valve surgery | ||||
| Mitral valve surgery | 1 (0.01) | 0 (0.00) | 1 (0.02) | 0.419 |
| Implantable pacemaker | 43 (0.46) | 19 (0.52) | 24 (0.43) | 0.533 |
| Implantable cardioverter defibrillator | 206 (2.21) | 62 (1.69) | 144 (2.56) | 0.005 |
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; HCM, hypertrophic cardiomyopathy.